A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies

Patrick H. Warnke, Andreas Humpe, Dirk Strunk, Sebastien Stephens, Frauke Warnke, Joerg Wiltfang, Katharina Schallmoser, Mohammad A. Alamein, Robert Bourke, Peter Heiner, Qin Liu

Research output: Contribution to journalArticleResearchpeer-review

34 Citations (Scopus)

Abstract

The transplantation of human stem cells seeded on biomaterials holds promise for many clinical applications in cranio-maxillo-facial tissue engineering and regenerative medicine. However, stem cell propagation necessary to produce sufficient cell numbers currently utilizes fetal calf serum (FCS) as a growth supplement which may subsequently transmit animal pathogens. Human platelet lysate (HPL) could potentially be utilized to produce clinical-grade stem cell-loaded biomaterials as an appropriate FCS substitute that is in line with clinically-applicable practice. The goal of this study was to investigate whether HPL can be successfully used to propagate human mesenchymal stem cells (HMSCs) seeded on clinically-approved collagen materials under clinically-applicable conditions using FCS as a control. HMSCs were isolated from bone marrow and cultured in the presence of 10% FCS or 10% HPL. Characterization of HMSCs was performed by flow cytometry and through osteogenic and adipogenic differentiation assays. Proliferative capacity of HMSCs on both matrices was investigated by mitochondrial dehydrogenase assays (WST) and tissue coverage scanning electron microscopy (SEM). The isolated HMSC differentiated into osteogenic and adipogenic cells authenticating the multipotentiality of the HMSCs. WST tests and the SEM images demonstrated that HPL was generally superior to FCS in promoting growth of seeded HMSCs. For all other tests HPL supported HMSCs at least equal to FCS. In conclusion, HPL is an effective growth factor to allow expansion of clinical-grade HMSCs on clinically-approved biomaterials for maxillofacial and oral implantology applications.

Original languageEnglish
Pages (from-to)153-161
Number of pages9
JournalJournal of Cranio-Maxillofacial Surgery
Volume41
Issue number2
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Mesenchymal Stromal Cells
Blood Platelets
Therapeutics
Biocompatible Materials
Serum
Electron Scanning Microscopy
Stem Cells
Regenerative Medicine
Stem Cell Transplantation
Tissue Engineering
Growth
Intercellular Signaling Peptides and Proteins
Flow Cytometry
Oxidoreductases

Cite this

Warnke, Patrick H. ; Humpe, Andreas ; Strunk, Dirk ; Stephens, Sebastien ; Warnke, Frauke ; Wiltfang, Joerg ; Schallmoser, Katharina ; Alamein, Mohammad A. ; Bourke, Robert ; Heiner, Peter ; Liu, Qin. / A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies. In: Journal of Cranio-Maxillofacial Surgery. 2013 ; Vol. 41, No. 2. pp. 153-161.
@article{ad6deed8ad884fbc90b431e2196bd8dd,
title = "A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies",
abstract = "The transplantation of human stem cells seeded on biomaterials holds promise for many clinical applications in cranio-maxillo-facial tissue engineering and regenerative medicine. However, stem cell propagation necessary to produce sufficient cell numbers currently utilizes fetal calf serum (FCS) as a growth supplement which may subsequently transmit animal pathogens. Human platelet lysate (HPL) could potentially be utilized to produce clinical-grade stem cell-loaded biomaterials as an appropriate FCS substitute that is in line with clinically-applicable practice. The goal of this study was to investigate whether HPL can be successfully used to propagate human mesenchymal stem cells (HMSCs) seeded on clinically-approved collagen materials under clinically-applicable conditions using FCS as a control. HMSCs were isolated from bone marrow and cultured in the presence of 10{\%} FCS or 10{\%} HPL. Characterization of HMSCs was performed by flow cytometry and through osteogenic and adipogenic differentiation assays. Proliferative capacity of HMSCs on both matrices was investigated by mitochondrial dehydrogenase assays (WST) and tissue coverage scanning electron microscopy (SEM). The isolated HMSC differentiated into osteogenic and adipogenic cells authenticating the multipotentiality of the HMSCs. WST tests and the SEM images demonstrated that HPL was generally superior to FCS in promoting growth of seeded HMSCs. For all other tests HPL supported HMSCs at least equal to FCS. In conclusion, HPL is an effective growth factor to allow expansion of clinical-grade HMSCs on clinically-approved biomaterials for maxillofacial and oral implantology applications.",
author = "Warnke, {Patrick H.} and Andreas Humpe and Dirk Strunk and Sebastien Stephens and Frauke Warnke and Joerg Wiltfang and Katharina Schallmoser and Alamein, {Mohammad A.} and Robert Bourke and Peter Heiner and Qin Liu",
year = "2013",
month = "3",
doi = "10.1016/j.jcms.2012.07.003",
language = "English",
volume = "41",
pages = "153--161",
journal = "Journal of Cranio-Maxillo-Facial Surgery",
issn = "1010-5182",
publisher = "Churchill Livingstone",
number = "2",

}

Warnke, PH, Humpe, A, Strunk, D, Stephens, S, Warnke, F, Wiltfang, J, Schallmoser, K, Alamein, MA, Bourke, R, Heiner, P & Liu, Q 2013, 'A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies' Journal of Cranio-Maxillofacial Surgery, vol. 41, no. 2, pp. 153-161. https://doi.org/10.1016/j.jcms.2012.07.003

A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies. / Warnke, Patrick H.; Humpe, Andreas; Strunk, Dirk; Stephens, Sebastien; Warnke, Frauke; Wiltfang, Joerg; Schallmoser, Katharina; Alamein, Mohammad A.; Bourke, Robert; Heiner, Peter; Liu, Qin.

In: Journal of Cranio-Maxillofacial Surgery, Vol. 41, No. 2, 03.2013, p. 153-161.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies

AU - Warnke, Patrick H.

AU - Humpe, Andreas

AU - Strunk, Dirk

AU - Stephens, Sebastien

AU - Warnke, Frauke

AU - Wiltfang, Joerg

AU - Schallmoser, Katharina

AU - Alamein, Mohammad A.

AU - Bourke, Robert

AU - Heiner, Peter

AU - Liu, Qin

PY - 2013/3

Y1 - 2013/3

N2 - The transplantation of human stem cells seeded on biomaterials holds promise for many clinical applications in cranio-maxillo-facial tissue engineering and regenerative medicine. However, stem cell propagation necessary to produce sufficient cell numbers currently utilizes fetal calf serum (FCS) as a growth supplement which may subsequently transmit animal pathogens. Human platelet lysate (HPL) could potentially be utilized to produce clinical-grade stem cell-loaded biomaterials as an appropriate FCS substitute that is in line with clinically-applicable practice. The goal of this study was to investigate whether HPL can be successfully used to propagate human mesenchymal stem cells (HMSCs) seeded on clinically-approved collagen materials under clinically-applicable conditions using FCS as a control. HMSCs were isolated from bone marrow and cultured in the presence of 10% FCS or 10% HPL. Characterization of HMSCs was performed by flow cytometry and through osteogenic and adipogenic differentiation assays. Proliferative capacity of HMSCs on both matrices was investigated by mitochondrial dehydrogenase assays (WST) and tissue coverage scanning electron microscopy (SEM). The isolated HMSC differentiated into osteogenic and adipogenic cells authenticating the multipotentiality of the HMSCs. WST tests and the SEM images demonstrated that HPL was generally superior to FCS in promoting growth of seeded HMSCs. For all other tests HPL supported HMSCs at least equal to FCS. In conclusion, HPL is an effective growth factor to allow expansion of clinical-grade HMSCs on clinically-approved biomaterials for maxillofacial and oral implantology applications.

AB - The transplantation of human stem cells seeded on biomaterials holds promise for many clinical applications in cranio-maxillo-facial tissue engineering and regenerative medicine. However, stem cell propagation necessary to produce sufficient cell numbers currently utilizes fetal calf serum (FCS) as a growth supplement which may subsequently transmit animal pathogens. Human platelet lysate (HPL) could potentially be utilized to produce clinical-grade stem cell-loaded biomaterials as an appropriate FCS substitute that is in line with clinically-applicable practice. The goal of this study was to investigate whether HPL can be successfully used to propagate human mesenchymal stem cells (HMSCs) seeded on clinically-approved collagen materials under clinically-applicable conditions using FCS as a control. HMSCs were isolated from bone marrow and cultured in the presence of 10% FCS or 10% HPL. Characterization of HMSCs was performed by flow cytometry and through osteogenic and adipogenic differentiation assays. Proliferative capacity of HMSCs on both matrices was investigated by mitochondrial dehydrogenase assays (WST) and tissue coverage scanning electron microscopy (SEM). The isolated HMSC differentiated into osteogenic and adipogenic cells authenticating the multipotentiality of the HMSCs. WST tests and the SEM images demonstrated that HPL was generally superior to FCS in promoting growth of seeded HMSCs. For all other tests HPL supported HMSCs at least equal to FCS. In conclusion, HPL is an effective growth factor to allow expansion of clinical-grade HMSCs on clinically-approved biomaterials for maxillofacial and oral implantology applications.

UR - http://www.scopus.com/inward/record.url?scp=84872685697&partnerID=8YFLogxK

U2 - 10.1016/j.jcms.2012.07.003

DO - 10.1016/j.jcms.2012.07.003

M3 - Article

VL - 41

SP - 153

EP - 161

JO - Journal of Cranio-Maxillo-Facial Surgery

JF - Journal of Cranio-Maxillo-Facial Surgery

SN - 1010-5182

IS - 2

ER -